Approval · Notice of Compliance 33692 · 2024
JEMPERLI: Notice of Compliance 33692
Issued July 23, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33692
- Date
- July 23, 2024
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfillment of commitments 2a, 2b, 2c, and 2d of the Letter of Undertaking dated November 18, 2021 issued under NDS control number 251105
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JEMPERLI | Not yet assigned | — |
Medicinal ingredients
- DOSTARLIMAB 50 MG per ML